LOTUS PHARMACEUTICAL CO., LTD. establish LOTUS Pharma Co., Ltd. as 100% subsidiary company.

LOTUS and EPS Complete Agreement for OMS0728 in China.
LOTUS, EPS Co., Ltd. and TMRC Co., Ltd. announced that the parties completed a Sales Agreement of OMS0728 for the Chinese market. Under the terms of the agreement, LOTUS will develop OMS0728 and obtain its approval from SFDA , and EPS will obtain a sales right in the Chinese market.

1st patient-in of OMS210 P2a clinical trials.

P2/3 clinical trials of OMS0728 begin in China.

P2a (POC) clinical trials of OMS210 for the treatment of IBS begin in 5 EU countries.

License-in contract of LTS1115 for its exclusive world-wide development, manufacturing and sales rights, and begin non-clinical studies in Japan for target indication of autoimmune diseases including RA and SLE.

Move Head office to new address.

P1 multiple dose study of OMS210 begin in UK.